18 August 2021 - The World Health Organization called on Wednesday on Roche to ensure fair distribution of its arthritis drug used to treat COVID-19 patients as supplies of the drug run low due to rising cases driven by the more infectious Delta variant.

In a statement on Monday, Roche's U.S. unit Genentech warned of a global shortage of tocilizumab, sold by Roche as Actemra and RoActemra, which will last at least for the next few weeks.

Read Reuters article